Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
BetterInvesting Magazine has selected Lowe's Cos. (NYSE: LOW) as its 'Stock to Study' for the June/July 2025 double issue, suggesting the stock warrants further investigation from a valuation perspective. The magazine provides comprehensive fundamental data including sales, earnings, pre-tax profit, and return on equity through the National Association of Investors platform.
Additionally, the publication's Editorial Advisory and Securities Review Committee has identified ICON PLC (NASDAQ: ICLR) for fundamental review in the same issue, specifically from an undervalued perspective. The committee's analysis is conducted by six CFA-qualified members.
ICON (NASDAQ: ICLR) has become the first large Clinical Research Organization to fully integrate Medidata Clinical Data Studio into its clinical workflows. This strategic implementation allows ICON to leverage AI-powered technology for unified data management across Medidata and non-Medidata sources.
The integration enhances ICON's ability to streamline data review, central monitoring, and medical review processes through AI and statistical modeling. This advancement is particularly significant for ICON's Clinical Data Science group, which specializes in risk-based quality management.
The partnership builds on a 20-year relationship between ICON and Medidata, during which they have collaborated on more than 1,700 studies, with over 400 currently active studies across various therapeutic areas including oncology, central nervous system, and vaccine therapies. ICON also utilizes Medidata eCOA and Medidata Designer for clinical operations management.
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, has announced upcoming presentations at two major healthcare investor conferences. Dr. Steve Cutler, CEO of ICON plc, is scheduled to present at:
- The Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:00 am ET
- The Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025, at 8:30 am ET
Any updates to these events and live webcast links will be available in the Investor section of ICON's website under 'Events'.
ICON plc (NASDAQ: ICLR) and Mural Health Technologies have announced a strategic partnership to implement Mural Link, a comprehensive participant management and payments platform for clinical trials. The collaboration aims to enhance trial participation experience and efficiency.
Through this partnership, ICON will leverage Mural Link's features including:
- Clinical trial participant payment systems
- Tax management capabilities
- Travel and concierge support
- Site-participant communication tools
- Advanced reporting and analytics
A key highlight is Mural Health's fee-free debit card option, designed to eliminate financial barriers to trial participation. The partnership focuses on increasing the recruitable patient population, particularly among historically underrepresented groups, while reducing participant-level operational challenges that contribute to patient attrition.
ICON (ICLR) reported its Q4 and full-year 2024 results, with Q4 net business wins of $2,413 million and a book-to-bill ratio of 1.18. Full-year net business wins reached $9,974 million with a 1.20 book-to-bill ratio. The company's closing backlog grew to $24.7 billion, up 8.3% year-over-year.
Q4 revenue was $2,041.1 million, down 1.2% year-over-year, while full-year revenue increased 2.0% to $8,282 million. Q4 adjusted EBITDA was $422.6 million (20.7% of revenue), and full-year adjusted EBITDA reached $1,735.8 million (21.0% of revenue). The company achieved $1.1 billion in free cash flow for 2024 and maintained a net debt of $2.9 billion.
ICON repurchased $400 million worth of stock in Q4 at an average price of $217 and authorized a new $750 million share repurchase program. The company reaffirmed its 2025 revenue guidance of $8,050-$8,650 million and adjusted EPS guidance of $13.00-$15.00.
ICON plc (NASDAQ: ICLR) announced the expansion of its artificial intelligence (AI) tools portfolio to enhance clinical trial processes. The company has established an AI Centre of Excellence, supported by an AI Governance Committee, to develop and deploy AI solutions.
The new solutions include: iSubmit for automated document management, Mapi Research Trust COA for clinical outcome assessments, FORWARD+ for resource management, Study Start-up Site Contracts for contract drafting, and OMR AI Navigation Assistant for operational metrics analysis.
ICON received an Enterprise Ireland grant to further enhance its AI capabilities. A recent company survey revealed that 13% of biopharma companies face challenges in systematically incorporating AI technologies despite their heavy use in single development programs.
ICON plc (NASDAQ: ICLR), a healthcare intelligence and clinical research organization, has scheduled its fourth quarter and full year 2024 earnings release for Wednesday, February 19, 2025, after market close. The company will host a conference call and webcast to discuss the financial results on Thursday, February 20, 2025, at 8:00am ET. A replay of the webcast will be available approximately one hour after the call concludes. Investors can access the webcast through the Events section of ICON's investor relations website.
ICON plc (NASDAQ: ICLR) has released its financial guidance for 2025, projecting revenue between $8,050 - $8,650 million, representing approximately 1% growth at the midpoint compared to 2024. The company expects adjusted earnings per share between $13.00 - $15.00, flat compared to 2024's guidance midpoint.
The company reaffirmed its 2024 guidance with revenue between $8,260 - $8,300 million and adjusted earnings per share of $13.90 - $14.10. ICON repurchased $400 million worth of stock in Q4 2024 at an average price of $217, bringing the full-year 2024 repurchase total to $500 million.
CEO Dr. Steve Cutler noted that ICON faces challenges from cautious spending by biopharma customers and expects a transition period with headwinds from its top two customers. However, growth in strategic partnerships is expected to partially offset these challenges. The company reported a trailing twelve-month book-to-bill ratio of 1.2 times in Q4.
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has released a survey of 120+ biotech and pharma professionals focusing on neurodegenerative disorder treatments. Despite recent successes in Alzheimer's disease treatments, challenges in neurodegenerative trials persist. ICON's new whitepaper, ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s R&D', highlights the potential of underutilized trial methodologies.
Biomarkers are important for early identification of trial participants. 97% of respondents use biomarkers, and 59% leverage AI for biomarker detection. However, biomarkers are not fully optimized, potentially making trials longer and costlier. Innovative trial designs are underused, with only 28% using adaptive designs, 22% using historic controls, and 19% utilizing master protocols.
Peter Schueler, MD, Senior VP at ICON, emphasizes the complexity of neurodegenerative research and the need for cost-effective and validated tools. Despite challenges, 87% of respondents plan diversified R&D investments, and AI is predominantly used in early development stages. Only 29% see collaboration as a key acceleration factor. Further industry engagement is essential to replicate and improve upon recent clinical successes.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organisation, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Dr. Steve Cutler, CEO of ICON plc, is scheduled to present at the conference on Tuesday, January 14, 2025 at 3:45pm PST. The company will provide updates regarding any changes to the event and access to the live webcast through the Investor section of their website under the Events tab.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
